Education
About Us
Working with TipRanks
Follow Us
Seelos Therapeutics (SEELQ)
OTHER OTC:SEELQ
SEELQ Stock Chart & Stats
$0.18
$0.10(39.94%)
At close: 4:00 PM EST
$0.18
$0.10(39.94%)
Day’s Range― - ―
52-Week Range<$0.01 - $174.08
Previous CloseN/A
Volume6.71K
Average Volume (3M)8.69K
Market Cap
$112.00
Enterprise Value$11.36M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta30.22
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,124,121
10 Day Avg. Volume2,464
30 Day Avg. Volume8,686
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap101.47K
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline PotentialSeelos' focus on CNS disorders and rare diseases positions it well in niche markets with high unmet needs, potentially leading to successful drug approvals and partnerships.
Revenue Generation StrategyThe company's strategy to generate revenue through strategic partnerships and licensing agreements can provide financial support and enhance its R&D capabilities.
Gross Profit MarginA 100% gross profit margin indicates effective cost management in its operations, which is crucial for sustaining profitability once products are commercialized.
Bears Say
Negative Stockholders' EquityNegative equity suggests liabilities exceed assets, posing solvency risks and necessitating financial restructuring to ensure long-term viability.
Cash Flow ChallengesOngoing negative cash flow indicates persistent cash outflows, which could threaten sustainability without new financing or successful product commercialization.
Operational LossesSignificant operational losses highlight inefficiencies and the need for cost management improvements to achieve profitability and long-term growth.
SEELQ FAQ
What was Seelos Therapeutics’s price range in the past 12 months?
Seelos Therapeutics lowest stock price was <$0.01 and its highest was $174.08 in the past 12 months.
What is Seelos Therapeutics’s market cap?
Seelos Therapeutics’s market cap is $112.00.
When is Seelos Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Seelos Therapeutics’s earnings last quarter?
Currently, no data Available
Is Seelos Therapeutics overvalued?
According to Wall Street analysts Seelos Therapeutics’s price is currently Overvalued.
Does Seelos Therapeutics pay dividends?
Seelos Therapeutics does not currently pay dividends.
What is Seelos Therapeutics’s EPS estimate?
Seelos Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Seelos Therapeutics have?
Seelos Therapeutics has 1,124,121 shares outstanding.
What happened to Seelos Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Seelos Therapeutics?
Currently, no hedge funds are holding shares in SEELQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Seelos Therapeutics
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. Its portfolio include late-stage clinical assets targeting psychiatric and movement disorders. The company is headquartered in New York, NY.
Ownership Overview
―
Insiders
1.04% Mutual Funds
1.83% Other Institutional Investors
97.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---